THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTATION OF STANDARDIZED SEROLOGY TESTING FOR ITS INTE

应向治疗开发分支提供以下支持： ·与Leidos Biomedical Research，Inc.的高级生物医学计算科学合作，继续开展“罕见疾病综合数据资源”项目; ·分析验证和非GMP和GMP生产的原料药和药品批次; ·支持GMP和/或非GMP产品项目的稳定性研究; ·生物分布/成像和药代动力学研究; ·生物分析方法开发咨询服务; ·支持临床前和/或临床阶段项目的监管服务; ·电子显微镜研究; ·基因表达和蛋白质组数据分析以及基于细胞的筛选研究; ·蛋白质组学分析，基于细胞的功效研究和犬比较肿瘤学的临床试验; ·实验室动物支持。

The following support shall be provided for Therapeutic Development Branch: • Continuation of the "Integrated Data Resource for Rare Diseases" working with Advanced Biomedical Computational Science at Leidos Biomedical Research, Inc.; • Assay validation and non-GMP and GMP manufacturing of batches of drug substance and drug product; • Stability studies to support projects with GMP and / or non-GMP products; • Biodistribution / imaging and pharmacokinetic studies; • Consulting services for development of bioanalytical methods; • Regulatory services to support preclinical and / or clinical-stage projects; • Electron microscopy studies; • Gene expression and proteomic data analyses and cell-based screening studies; • Proteomic profiling, cell-based efficacy studies, and clinical trials for canine comparative oncology; • Laboratory animal support.